规格 | 价格 | 库存 | 数量 |
---|---|---|---|
500mg |
|
||
1g |
|
||
Other Sizes |
|
药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments. Liver, heart, kidneys, muscle and adipose (perirenal and s.c.) /bovine/ tissues were collected from 6 animals for analysis of their hydrocarbon composition. Qualitative and quantitative determinations were carried out by gas chromatography and combined gas chromatography-mass spectrometry. Although differing in the proportions, a homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples. The isoprenoid hydrocarbons phytane and phytene (phyt-1-ene and phyt-2-ene) were also identified. (These findings have relevance to the health of humans consuming hydrocarbon-contaminated meats.) /n-Alkanes/ Metabolism / Metabolites Arthrobacter nicotianae KCC B35 isolated from blue-green mats densely covering oil sediments along the Arabian Gulf coast grew well on C10 to C40 n-alkanes as sole sources of carbon and energy. Growth on C20 to C40 alkanes was even better than on C10 to C18 alkanes. Biomass samples incubated for 6 hr with n-octacosane (C28) or n-nonacosane (C29) accumulated these compounds as the predominant constituent alkanes of the cell hydrocarbon fractions. The even chain hexadecane C16 and the odd chain pentadecane C15 were the second dominant constituent alkanes in C28 and C29 incubated cells, respectively. n-Hexadecane-incubated cells accumulated in their lipids higher proportions of C16-fatty acids than control cells not incubated with hydrocarbons. On the other hand, C28 and C29-incubated cells did not contain any fatty acids with the equivalent chain lengths, but the fatty acid patterns of the cell lipids suggest that there should have been mid-chain oxidation of these very long chain alkanes. This activity qualifies A. nicotianae KCC B35 to be used in cocktails for bioremediating environments polluted with heavy oil sediments. |
---|---|
毒性/毒理 (Toxicokinetics/TK) |
Toxicity Summary
IDENTIFICATION AND USE: Docosane is a solid n-alkane containing 22 carbon atoms (C22). Solid n-alkanes (paraffin waxes) are used in a variety of applications: as feeds for cracking them to gasoline blendstock materials, oxidation, and chlorination reactions. HUMAN EXPOSURE AND TOXICITY: There are no data available. ANIMAL STUDIES: A homologous series of n-alkanes ranging from n-C12-n-C31 was found in all samples of bovine tissues. Interactions The C-14 content of epidermis, dermis, subdermal muscle and certain other tissues was determined 48 hours following topical application of hexadecane-1-C-14 to the skin of guinea pigs. The effect of simultaneous application of U.S.P. heavy mineral oil, n-docosane, and heptane as well as hexadecane pre-treatment on the extent of penetration of hexadecane-1-C-14 was also measured. Large amounts of C-14 were found in the epidermis whereas relatively little accumulated in the dermis and underlying tissues. Each of the carrier vehicles reduced the amount of C-14 in the epidermis; whereas, docosane and mineral oil, but not heptane, reduced the amount of C-14 in the dermis and subdermal muscle. This correlated with the ability of heavy mineral oil and docosane, but not heptane, to decrease the dermatoxic effects of hexadecane. Pre-treatment of the skin with hexadecane 48 hours prior to application of hexadecane-1-C-14, if anything, increased the amount of the C-14 in the epidermis; however, pre-treatment with mineral oil:hexadecane reduced the amount of epidermal and dermal C-14 from a subsequent application of mineral oil:hexadecane-1-C-14. The results support the proposal that heavy mineral oil and alkanes with a chain length of over 20 carbon atoms reduce the dermatoxic effect of hexadecane by interfering with its penetration to the site of action. This site would appear to be either the deeper layers of epidermis or possibly the dermis. The increased uptake of hexadecane-C-14 by the epidermis following pretreatment with hexadecane provides a possible explanation for the more severe response seen with multiple hexadecane applications as opposed to a single application of the same amount of material. |
参考文献 |
|
其他信息 |
N-docosane is a solid. Insoluble in water. Used in organic synthesis, calibration, and temperature sensing equipment.
Docosane is a straight-chain alkane with 22 carbon atoms. It has a role as a plant metabolite. Docosane has been reported in Vanilla madagascariensis, Magnolia officinalis, and other organisms with data available. See also: Moringa oleifera leaf oil (part of). |
分子式 |
C22H46
|
---|---|
分子量 |
310.60
|
精确质量 |
310.36
|
CAS号 |
629-97-0
|
相关CAS号 |
Docosane-d46; 260411-88-9
|
PubChem CID |
12405
|
外观&性状 |
White to off-white solid
|
密度 |
0.778 g/mL at 25 °C(lit.)
|
沸点 |
369 °C(lit.)
|
熔点 |
42-45 °C(lit.)
|
闪点 |
>230 °F
|
蒸汽压 |
<1 mm Hg ( 21.1 °C)
|
折射率 |
1.4455
|
LogP |
8.828
|
tPSA |
0
|
氢键供体(HBD)数目 |
0
|
氢键受体(HBA)数目 |
0
|
可旋转键数目(RBC) |
19
|
重原子数目 |
22
|
分子复杂度/Complexity |
153
|
定义原子立体中心数目 |
0
|
SMILES |
C([H])([H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H]
|
InChi Key |
HOWGUJZVBDQJKV-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C22H46/c1-3-5-7-9-11-13-15-17-19-21-22-20-18-16-14-12-10-8-6-4-2/h3-22H2,1-2H3
|
化学名 |
docosane
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意: 本产品在运输和储存过程中需避光。 |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外实验) |
DMSO: 16.67 mg/mL (53.67 mM)
|
---|---|
溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 1.67 mg/mL (5.38 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 16.7 mg/mL澄清的DMSO储备液加入到400 μL PEG300中,混匀;再向上述溶液中加入50 μL Tween-80,混匀;然后加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 1.67 mg/mL (5.38 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 16.7mg/mL澄清的DMSO储备液加入到900μL 20%SBE-β-CD生理盐水中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 1.67 mg/mL (5.38 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2196 mL | 16.0979 mL | 32.1958 mL | |
5 mM | 0.6439 mL | 3.2196 mL | 6.4392 mL | |
10 mM | 0.3220 mL | 1.6098 mL | 3.2196 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。